• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Lab Anal Analysis of Clinical Features and Outcomes of 161 Patients With Severe and Critical COVID-19: A Multicenter Descriptive Study

tetano

Editor, Senior Moderator
J Clin Lab Anal


. 2020 Jun 2;e23415.
doi: 10.1002/jcla.23415. Online ahead of print.
Analysis of Clinical Features and Outcomes of 161 Patients With Severe and Critical COVID-19: A Multicenter Descriptive Study


Ming Shi[SUP] 1 [/SUP], Lianhua Chen[SUP] 2 [/SUP], Yadong Yang[SUP] 3 [/SUP], Jingpeng Zhang[SUP] 3 [/SUP], Ji Xu[SUP] 4 [/SUP], Gang Xu[SUP] 5 [/SUP], Bin Li[SUP] 6 [/SUP], Yiping Yin[SUP] 7 [/SUP]



Affiliations

Abstract

Background: This study aimed to investigate clinical characteristics, laboratory indexes, treatment regimens, and short-term outcomes of severe and critical coronavirus disease 2019 (COVID-19) patients.
Methods: One hundred and sixty one consecutive severe and critical COVID-19 patients admitted in intensive care unit (ICU) were retrospectively reviewed in this multicenter study. Demographic features, medical histories, clinical symptoms, lung computerized tomography (CT) findings, and laboratory indexes on admission were collected. Post-admission complications, treatment regimens, and clinical outcomes were also documented.
Results: The mean age was 59.38 ? 16.54 years, with 104 (64.60%) males and 57 (35.40%) females. Hypertension (44 [27.33%]) and diabetes were the most common medical histories. Fever (127 [78.88%]) and dry cough (111 [68.94%]) were the most common symptoms. Blood routine indexes, hepatic and renal function indexes, and inflammation indexes were commonly abnormal. Acute respiratory distress syndrome (ARDS) was the most common post-admission complication (69 [42.86%]), followed by electrolyte disorders (48 [29.81%]), multiple organ dysfunction (MODS) (37 [22.98%]), and hypoproteinemia (36 [22.36%]). The most commonly used antiviral drug was lopinavir/ritonavir tablet. 50 (31.06%) patients died, while 78 (48.45%) patients healed and discharged, and the last 33 (20.50%) patients remained in hospital. Besides, the mean hospital stay of deaths was 21.66 ? 11.18 days, while the mean hospital stay of discharged patients was 18.42 ? 12.77 days. Furthermore, ARDS (P < .001) and MODS (P = .008) correlated with increased mortality rate.
Conclusion: Severe and critical COVID-19 presents with high mortality rate, and occurrence of ARDS or MODS greatly increases its mortality risk.

Keywords: COVID-19; clinical features; clinical outcomes; laboratory indexes; post-admission complications.
 
Back
Top Bottom